• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Bio Rad Laboratories (BIO) Draws Focus As UBS Event Tests Whether It Is Fully Valued

    Simply Wall St·11/02/2026 01:27:49
    Listen to the news

    Bio-Rad Laboratories (BIO) is back on investors’ radar as CFO Roop K. Lakkaraju heads into a fireside chat at the UBS Global Healthcare Conference, alongside fresh guidance and order strength in its process chromatography business.

    Recent trading paints a mixed picture for Bio-Rad Laboratories. The share price is down 3.18% over the past day but still carries a 21.92% year to date share price return and a 16.47% total shareholder return over the past year, while the 5 year total shareholder return is down 48.71%. This suggests that current momentum around new guidance and the UBS appearance is emerging from a much weaker long term base.

    Scan beyond Bio-Rad Laboratories and compare it with a hand picked 34 healthcare AI stocks benefiting from rising investment in research tools and clinical diagnostics.

    The set up is simple. After a sharp rebound but a 5 year total shareholder return that is still down 48.71%, is most of Bio-Rad Laboratories’ upside already used up, or is the valuation case only starting to rebuild?

    Most Popular Narrative: 13% Overvalued

    On the latest numbers, the most followed valuation view puts Bio-Rad Laboratories at a fair value of $329, versus a last close of $372.18. That gap sets the context for the current excitement around process chromatography orders, ddPCR platforms, and the large buyback program.

    Resilience and stable growth in consumables and reagents, demonstrated by high single-digit growth, especially in the face of delayed academic and instrument funding, are shifting Bio-Rad's sales mix toward higher-margin, recurring revenues, supporting overall profitability and cash flow stability.

    Strategic operational actions, including lean initiatives, flexible supply chain management, and geographic diversification, have enabled Bio-Rad to offset tariff and reimbursement headwinds while benefiting from reduced regulatory trade risks, supporting improved operating margins and mitigating cost volatility.

    See why 7 investors see Bio-Rad Laboratories as 13% overvalued.

    Result: Fair Value of $329 (OVERVALUED)

    Still, pressure on Clinical Diagnostics in China and softer instrument demand in research labs could weaken Bio-Rad Laboratories’ margins and undercut the buyback-supported valuation story.

    Find out about the key risks to this Bio-Rad Laboratories narrative.

    Next Steps

    If this mix of optimism and caution around Bio-Rad Laboratories feels hard to reconcile, treat it as your prompt to examine the facts directly and move quickly to frame your own stance, starting with the 1 important warning sign.

    Looking for more investment ideas beyond Bio-Rad Laboratories?

    Do not stop your research with Bio-Rad Laboratories. Use the Simply Wall Street Screener to surface fresh opportunities that match the kind of portfolio you want to build.